PTSM: Pharmaceutical Technology Sourcing and Management, Aug 1, 2007 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, Aug 1, 2007
Global Feature
A Mid-Year Scorecard for Big Pharma
By Patricia Van Arnum
The financial performance of the pharmaceutical majors was generally favorable through the first half of 2007, with most companies reporting moderate to double-digit growth. Industry leader Pfizer, however, reported a sales decline for the second quarter and flat revenues through the first half of 2007. Pfizer Chairman and CEO Jeffrey Kindler says the company remains committed to its plans for cost-cutting, more outsourcing, and increasing its position in biologics.
Pharma Partner Focus
Vetter Pharma Invests in Sterile Manufacturing
By Patricia Van Arnum
The company begins production at a new $100-million manufacturing facility for prefilled injection systems, plans further investment in packaging facilities, and targets both early-phase development and commercial manufacture.
APIs
Improving Routes in API Manufacturing
By Patricia Van Arnum
Catalytic routes to producing atorvastatin and sitagliptin are recent advancements.
News
Mergers, acquisitions, and restructuring
A roundup of company moves and positioning from the pharmaceutical and biotechnology industries and contract service providers.
Expansions
A roundup of manufacturing and service expansions.
Agreements and pacts
The latest pacts from the pharmaceutical supply chain.
Regulatory and association news
The latest on active pharmaceutical ingredients in development and under commercial manufacture
People
People on the move

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here